NR3C2 and atrial fibrillation: A meta-analysis that included 7914 patients showed that mineralocorticoid receptor antagonists (MRAs) were associated with a significantly lower AF risk compared with no MRA treatment (15.0% versus 32.2%; odds ratio, 0.55; 95% CI, 0.44–0.70 [p < 0.00001]) [36].